Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.49 |
| ▸ | ANPEP | P15144 | 4/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.49 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.49 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817387 | 0.81 | LAP3 (0.47) | LAP3ANPEPRNPEPDNPEPCTSD | |
| SCHEMBL4818604 | 0.80 | LAP3 (0.46) | LAP3ANPEPRNPEPDNPEPCTSD | |
| SCHEMBL8735273 | 0.76 | LAP3 (0.48) | LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL27934994 | 0.75 | LAP3 (0.70) | LAP3ANPEPRNPEPDNPEPLTA4H | |
| Hydrochloric Acid SCHEMBL7401087 | 0.74 | LAP3 (0.68) | LAP3ANPEPRNPEPDNPEPLTA4H | |
| Hydrochloric Acid SCHEMBL4390244 | 0.74 | LAP3 (0.68) | LAP3ANPEPRNPEPDNPEPLTA4H | |
| Hydrochloric Acid SCHEMBL21457997 | 0.74 | LAP3 (0.68) | LAP3ANPEPRNPEPDNPEPLTA4H | |
| SCHEMBL4816877 | 0.74 | LAP3 (0.51) | LAP3ANPEPRNPEPDNPEPKMT2A | |
| SCHEMBL4043571 | 0.73 | REN (0.63) | LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL5224992 | 0.72 | BACE1 (0.55) | LAP3ANPEPRNPEPDNPEPCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | claimed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | claimed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | claimed |
| EP-1404328-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | claimed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-7358264-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | disclosed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | disclosed |
| US-6864290-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN, LLP (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1404328-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | disclosed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | LAP3 286/4885ANPEP 63/4885RNPEP 97/4885 |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | LAP3 286/4885ANPEP 63/4885RNPEP 97/4885 |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | LAP3 321/4885ANPEP 84/4885RNPEP 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.